Pfizer Corporation

Pfizer Products Inc.

Douglas J M Allen

Robert J Rafka

Colman B Ragan

Timothy Norris

Zheng Jane Li

Peter Robert Rose

Joseph Francis Krzyzaniak

Frank R Busch

Derek Lawrence Tickner

Michael Jon Gumkowski

Daniel R Arenson

Ravi Mysore Shankar

Barry J Morton

Troy Anthony Appleton

Harry O Tobiassen

David B Joseph

Susan L Orrill

Kevin M Nepveux

David Joseph Muehlbauer

S Sonja Sekulic

Charles Kwon-Fung Chiu

Nancy A Sage

This invention relates to a novel crystalline diphosphate salt of (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[[2,6-dideoxy-3-C-methyl-3-O-methyl-4-C-[(propylamino)methyl]-&#x3b1;-L-ribo-hexopryanosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-&#x3b2;-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one that is useful as an antibacterial and antiprotozoal agent in mammals. This invention also relates to pharmaceutical compositions containing the free base of the diphosphate salt and the methods of treating bacterial and protozoal infections in mammals by administering the free base of the diphosphate to mammals requiring such treatment. The free base of the diphosphate salt of the present invention possesses potent activity against various bacterial and protozoal infections when given by parenteral application to mammals.

Diphosphate salt of a 4&#x2033;&#x2014;substituted-9-deoxo-9 A&#x2014;AZA&#x2014;homoerythromycin derivatives and its pharmaceutical composition

This invention relates to a novel crystalline diphosphate salt of (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[[2,6-dideoxy-3-C-methyl-3-o-methyl-4-C-[(propylamino)methyl]-&#x3b1;-L-ribo-hexopryanosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-&#x3b2;-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one that is useful as an antibacterial and antiprotozoal agent in mammals. This invention also relates to pharmaceutical compositions containing the free base of the diphosphate salt and the methods of treating bacterial and protozoal infections in mammals by administering the free base of the diphosphate to mammals requiring such treatment. The free base of the diphosphate salt of the present invention possesses potent activity against various bacterial and protozoal infections when given by parenteral application to mammals.

Diphosphate salt of A 4&#x2033;-substituted-9-deoxo-9A-AZA-9A-homoerythromycin derivative and its pharmaceutical composition

N-(indole-2-carbonyl)-b-alaninamide crystal forms

Crystalline forms of macrolide antibiotic

This invention relates to a novel crystalline diphosphate salt of (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-&lsqb;&lsqb;2,6-dideoxy-3-C-methyl-3-O-methyl-4-C-&lsqb;(propylamino)methyl&rsqb;-&agr;-L-ribo-hexopryanosyl&rsqb;oxy&rsqb;-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-11-&lsqb;&lsqb;3,4,6-trideoxy-3-(dimethylamino)-&bgr;-D-xylo-hexopyranosyl&rsqb;oxy&rsqb;-1-oxa-6-azacyclopentadecan-15-one that is useful as an antibacterial and antiprotozoal agent in mammals. This invention also relates to pharmaceutical compositions containing the free base of the diphosphate salt and the methods of treating bacterial and protozoal infections in mammals by administering the free base of the diphosphate to mammals requiring such treatment. The free base of the diphosphate salt of the present invention possesses potent activity against various bacterial and protozoal infections when given by parenteral application to mammals.

Diphosphate salt of a 4&Prime;-substituted-9-deoxo-9A-AZA-9A- homoerythromycin derivative and its pharmaceutical composition

Crystalline forms of (3S-trans)-2-&lsqb;3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl&rsqb;-4-(trifluoromethyl)-benzoic acid

Non-hygroscopic, azithromycin (9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin) dihydrate and a process therefor.

Azithromycin dihydrate

Two crystalline polymorphic forms of (2-Benzhydryl-1-azo-bicyclo(2.2.2&rsqb;Octyl-3-yl)-(5-iso-propyl-2-methoxybenzyl)amine dihydrochloride dihydrate are Form I and Form II. The pharmaceutical composition containing at least are of these polymorphs has advantageous stability for formulation to treat emesis in patients receiving chemotherapy. The administration of this pharmaceutical composition is conventional oral by preferably tablet or capsule or intravenous. A method of making Forms I and II is also disclosed.

Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions

This invention relates to suspensions for oral administration comprising novel trovafloxacin zwitterionic crystals, and processes for preparing such crystals. This invention further relates to other pharmaceutical compositions comprising these novel crystals, and to methods of using these suspensions, and these novel crystals in such other dosage forms, for treating bacterial infections in mammals.

Trovafloxacin oral suspensions

The present invention relates to the process for preparing a compound of the formula

Process for preparing 5-lipoxygenase inhibitors

Growing community of inventors

New London, CT, United States of America

Douglas J M Allen